Rabbit study picks Neurospray device for intranasal AmyP53 ahead of Phase 1

The wire

1. 01Six spray devices were compared; two Neurospray systems gave narrower plume angles and higher olfactory-region deposition, and delivered AmyP53 with ganglioside binding intact.
2. 02AmyP53 is positioned as a first-in-class peptide blocking amyloid oligomer formation in Alzheimer's and Parkinson's, and device selection is a gating step for its planned Phase 1.
3. 03Data come from deposition assays and a rabbit model; no human pharmacokinetic or efficacy results are reported and the trial has not yet begun.

From the source

An Optimal Spray Device for the Nose-to-Brain Delivery of AmyP53, an Adaptive Therapeutic Peptide for Alzheimer's and Parkinson's Diseases

Pharmaceutics · 2026 Aug 10 · Farias G, Chahinian H, Hauchard N et al.